Tag: bellerophon therapeutics

November 12, 2019

Bellerophon Announces Positive Data from INOpulse Study

The company's clinical study of INOpulse is for the treatment of pulmonary hypertension associated with interstitial lung disease.
November 7, 2019

Bellerophon Presents Data of Ongoing Phase 2/3 Study of INOpulse

The company will present data from Cohort 1 of its ongoing Phase 2/3 clinical trial of INOpulse in San Antonio,...
September 16, 2019

Bellerophon Gets Orphan Drug Designation for Nitric Oxide

The designation has been given by the US Food and Drug Administration to treat patients with idiopathic pulmonary fibrosis.
January 28, 2019

Bellerophon to Present Clinical Data Supporting Actigraphy as a Clinically Meaningful Endpoint

Bellerophon Therapeutics (Nasdaq:BLPH) a clinical-stage biotherapeutics company, today announced that data from the Company’s ongoing INOpulse Phase 2b clinical trial...
January 13, 2019

5 Top Weekly NASDAQ Biotech Stocks: Index Up During JPM Week

Axsome Therapeutics, Checkpoint Therapeutics, Bellerophon Therapeutics, Enochian Bioscience and Equillium were last week's top gainers.
December 16, 2018

5 Top Weekly NASDAQ Biotech Stocks: Innovate Leads the Pack

Innovate Biopharmaceuticals, Aridis Pharmaceuticals, Imprimis Pharmaceuticals, Achaogen and SynthoRx were last week's top gainers.
November 18, 2018

5 Top Weekly NASDAQ Biotech Stocks: Cocrystal on Top

Cocrystal Pharma, Ra Pharmaceuticals, Avenue Therapeutics, Imprimis Pharmaceuticals and Nightstar Therapeutics were last week's top gainers on the NASDAQ Biotechnology...